Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today that the first patient in a Phase 1/2 clinical trial for ABO-101 (AAV-NAGLU), a single treatment gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB), has been dosed at Nationwide Children's Hospital, Columbus, Ohio.
"With the dosing of the first patient with Sanfilippo syndrome type B, we are excited to begin enrolling our third gene therapy clinical trial targeting rare diseases," stated Timothy J. Miller, Ph.D., President and CEO of Abeona. "Having observed positive efficacy data and a strong safety profile in our MPS IIIA program, we look forward to further validating the clinical translation of this investigational gene therapy. This trial is the culmination of many years of research and development, and none of it would have been possible without continued support from the Sanfilippo patient advocacy community."
ABO-101 has been granted Orphan Product Designation by the U.S. Food and Drug Administration (FDA) and received Rare Pediatric Disease Designation as a pre-requisite component of the FDA's Priority Review Voucher process. The ABO-101 clinical study is supported by a 25-subject MPS III Natural History Study conducted at Nationwide Children's Hospital.
"MPS IIIB is a devastating and deadly lysosomal storage disease with no approved treatments available. Caused by a single gene defect, the disease afflicts children, many of whom do not reach adulthood. The ABO-101 gene therapy approach advances the potential of AAV gene therapy as a treatment paradigm for addressing this relentlessly progressive disease," noted Kevin M. Flanigan, M.D., Director and Principal Investigator with the Center for Gene Therapy at Nationwide Children's Hospital.
About ABO-101 (AAV-NAGLU): ABO-101 is Abeona's first-in-human, adeno-associated viral (AAV)-based gene therapy for MPS III (Sanfilippo syndrome). Treatment involves a one-time intravenous delivery of a functioning copy of the N-acetyl-A-D-glucosaminidase (NAGLU) gene to cells of the central nervous system (CNS) and peripheral organs, with the aim of correcting the effects that result from the genetic aberrations that are the root cause of the disease. Following administration of a single dose in Sanfilippo preclinical animal models, ABO-101 induced cells in the CNS and peripheral organs to produce the missing NAGLU enzyme, which then restored the underlying sugar (GAG) storage pathology to normal levels in cells. Preclinical in vivo efficacy studies in Sanfilippo syndrome animal model have demonstrated functional benefits that continue for months after treatment. A single dose of ABO-101 significantly restored normal cell and organ function, corrected cognitive defects, increased neuromuscular function and normalized the lifespan of animals with MPS IIIB after treatment compared to untreated control animals. These results are consistent with studies from several laboratories suggesting AAV treatment could potentially benefit patients with Sanfilippo syndrome. Safety and efficacy studies of AAV gene therapy treatments for Sanfilippo syndrome have recently been published in several peer-reviewed scientific journals.
About MPS IIIB: (also known as Sanfilippo syndrome type B) is a genetic, progressive, and devastating rare lysosomal storage disease. In patients with MPS IIIB, genetic mutations result in a marked decrease in NAGLU enzyme activity, which leads to accumulation of heparan sulfate (HS) in the brain and other organs as well as progressive brain atrophy with cortical gray matter volume loss. The accumulation of abnormal HS results in neurocognitive decline, behavioral disturbances, speech loss, increasing loss of mobility, and premature death. MPS IIIB typically presents in children during the first few years of life, and 70% of patients do not reach 18 years of age. There are no approved treatments for MPS IIIB.
About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing its proprietary vector platform, AIM(TM), for next generation product candidates.
Vice President, Investor Relations
Abeona Therapeutics Inc.
Berry & Company Public Relations
+1 (212) 253-8881
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including the statement that AAV treatment could potentially benefit patients with Sanfilippo syndrome. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to obtain any necessary intellectual property to commercialize any of our products; the ability to achieve or obtain necessary regulatory approvals and licenses; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer18.10.2018 14:03 | Pressemelding
NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Siffert, M.D. as Head of Research and Development and Chief Medical Officer. As a result, former Chief Medical Officer Juan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. The Company also announced the appointment of Neena Patil, J.D. as General Counsel and Corporate Secretary. Both Dr. Siffert and Ms. Patil report to Chief Executive Officer, Carsten Thiel, Ph.D. “I am very pleased to welcome João and Neena to Abeona, and confident in their abilities to make important contributions to the future growth of our company,” said Dr. Thiel. “João has an ideal blend of clinical, scientific, and regulatory experience to reference as we look to advance our clinical and pre-clinical can
Meltwater and Dow Jones Announce Global Partnership to Provide Premium Content18.10.2018 14:00 | Pressemelding
SAN FRANCISCO and NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media intelligence, today announces the launch of a partnership with Dow Jones, a global provider of news and business information, to provide premium licensed content from Dow Jones Factiva into the Meltwater Media Intelligence platform. This partnership will give Meltwater’s PR and communications clients the ability to monitor and analyze premium licensed content across thousands of Factiva news sources globally, including: The Wall Street Journal, America’s largest newspaper by paid circulation; Barron’s; MarketWatch; and Dow Jones Newswires. “Meltwater provides our clients with the most comprehensive content network globally, across news, social media and broadcast media. This new Dow Jones partnership will further strengthen our leadership position and allow our clients to access licensed content from some of the most highly-respected news outlets in the world. We’re excited about this part
SEMAFO Provides Notice of Third Quarter 2018 Results Release and Conference Call 18.10.2018 13:30 | Pressemelding
MONTREAL, Oct. 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX, OMX: SMF) invites you to participate in a conference call on November 7, 2018 at 10:00 AM EST with senior management during which they will review the Corporation's third quarter 2018 financial and operational results. SEMAFO's financial statements and management's discussion and analysis for the third quarter 2018 will be released on November 6 after market hours and will be available in the “Investor Relations” section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO’s website at www.semafo.com . Tel. local & overseas: +1 (647) 788 4922 Tel. North America: 1 (877) 223 4471 Webcast: www.semafo.com Replay overseas: +1 (416) 621 4642 Replay N. America: 1 (800) 585 8367 Replay pass code: 2823689 Expiration: December 7, 2018 About SEMAFO SEMAFO is a Canadian-b
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting18.10.2018 13:30 | Pressemelding
EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. Data to be presented across the Alzheimer’s disease clinical development portfolio, including aducanumab, BAN2401 and elenbecestat CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27). The data being presented are part of Biogen’s ongoing research programs targeting possible causes of the disease through multiple modalities. “We are excited to engage with the scientific community at CTAD, to share learnings from our Alzheimer’s disease clinical research and to learn from the work of our colleagues around the world. We have hopes that our
Biome Grow Announces Listing on the Frankfurt Stock Exchange under symbol 60TA18.10.2018 13:30 | Pressemelding
TORONTO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- (CSE: BIO) – Biome Grow (“Biome” or the “Company”) (CSE:BIO) is pleased to announce that the Company’s common shares have been listed on the Frankfurt Stock Exchange under the trading symbol “6OTA”. The Company’s common shares continue to be listed on the Canadian Securities Exchange (“CSE”) under the trading symbol “BIO”. “Biome is developing its production base in Canada with an eye to becoming a leader in the international medical cannabis market. Listing on the Frankfurt Stock Exchange will give Biome increased access to European and other international investors and positions Biome well for international growth and development opportunities,” said CEO Khurram Malik. The Frankfurt Stock Exchange is one of the world’s largest trading centres for securities. With a share in turnover of around 90 per cent, it is the largest of Germany’s seven stock exchanges and it is an international trading centre, which is reflected in the structure of its
Homology Medicines Presents Long-Term Efficacy Data of a Single Dose of Gene Therapy Development Candidate for Treatment of Phenylketonuria18.10.2018 13:00 | Pressemelding
BEDFORD, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today long-term efficacy data of a single dose of its lead gene therapy candidate for the treatment of phenylketonuria (PKU), an inborn error of metabolism. The presentation at the European Society of Gene & Cell Therapy (ESGCT) Annual Congress showed sustained reduction of phenylalanine (Phe), the surrogate biomarker for PKU. Homology plans to begin and report initial clinical data from a Phase 1/2 gene therapy trial in adults with PKU in 2019. “We are excited to share this long-term data demonstrating that our gene therapy development candidate can address and correct the genetic cause of PKU in a well-established animal disease model,” said Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines. “Our approach, which delivers functional copies of the human PAH gene, may offer a one-time potential cure for PKU that would restore the natural b
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom